# US 2021/0080441 A1 · Compositions containing cannabinoid analog conjugates and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0080441 A1
- Document ID: US20210080441A1
- Status: Published application
- Kind: A1
- Application number: 17/088,458
- Filed: 2020-11-03
- Published: 2021-03-18
- Earliest claimed: 2014-02-05
- Assignees: Vyripharm Enterprises, LLC
- Applicants: Vyripharm Enterprises, LLC
- Inventors: Jerry L. BRYANT, JR.; Tori M. STRONG
- Web page: https://patentgrep.com/patent/US20210080441A1

## CPC

- G01N 33/0098: {Plants or trees (wood G01N33/46)}
- G01N 33/15: Medicinal preparations {; Physical properties thereof, e.g. dissolubility}
- G01N 33/948: {Sedatives, e.g. cannabinoids, barbiturates (opiates G01N33/9486)}
- G06Q 10/087: Inventory or stock management, e.g. order filling, procurement or balancing against orders
- G16H 70/40: relating to drugs, e.g. their side effects or intended usage
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G06Q: INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Embodiments of the disclosure provide a method of man-aging information related to a cannabis product across a distributed validated system. The method includes enabling an authorized user to create a plurality of data containing genetic profile of a seed, plant growth conditions of a crop, and manufacturing information used for production of the cannabis product, and measurements of quality and quantity of desired components and undesired components in the cannabis product. The method includes associating the plurality of data to a record which is identified by a unique identifier. The method includes storing the record into a memory for access by one or more of a plurality of authorized users using the unique identifier. The method includes analyzing the cannabis product to determine the quality and quantity of desired components and undesired components in the cannabis product. The method includes determining concentration of cannabinoids in the cannabis product.

## Claims

### Claim 1

A composition comprising a conjugate of a label, a chelator, and a cannabinoid analog.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the label is a radionuclide.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the label is one or more of Technetium-99, Gallium-68, Copper-60, Copper-64, Indium-Ill, Holmium-166, Rhenium-186, Rhenium-188, Yttrium-90, Lutetium-177, Radium-223, or Actinium-225.

### Claim 4 (depends on 1)

The composition claim 1, wherein the label is configured to facilitate contrast-enhanced imaging, when the composition is administered to a mammal during use.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the cannabinoid analog is an immune check point cannabinoid receptor ligand.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the cannabinoid analog is a synthetic cannabinoid receptor agonist.

### Claim 7

The composition as in any one of the preceding claims, wherein the cannabinoid analog is a natural cannabinoid receptor agonist.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the cannabinoid analog is an aminoalkylindole.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the cannabinoid analog is a cannabinoid receptor inverse agonist.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the cannabinoid analog belongs to the group consisting of anandamide (AEA), 2-arachidonoylglycerol (2-AG), noladin ether, virodhamine, and N-arachidonylodopamine (NADA).

### Claim 11 (depends on 1)

The composition of claim 1, wherein the cannabinoid analog is a diarylopyrazole.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the chelator is an aminated or an acid chelator.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the chelator is a cyclam.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the cannabinoid analog is cyclam-1′-acetyl [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the cannabinoid analog is cyclam-1′-propyl [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide.

### Claim 16 (depends on 1)

A method for diagnosing a medical condition in a human subject, the method comprising administering to a human subject an effective amount of the composition of claim 1.

### Claim 17 (depends on 1)

A method of imaging a plurality of cancer cells, the method comprising:
administering to a human patient an effective amount of the composition of claim 1.

### Claim 18 (depends on 1)

A method for treating a cancer amenable to treatment with a cannabinoid, the method comprising:
administering to a human subject in need thereof an effective amount of the composition of claim 1.

### Claim 19 (depends on 1)

A method for treating a neurologic disorder amenable to treatment with a cannabinoid, the method comprising:
administering to a human subject in need thereof an effective amount of the composition of claim 1.

### Claim 20 (depends on 1)

A method for alleviating pain in a human subject, the method comprising:
administering to a human subject in need thereof an effective amount of the composition of claim 1.

### Claim 21

A kit for imaging cells, comprising:
a predetermined quantity of a conjugate of a chelator and a medical cannabinoid analog; and
a predetermined quantity of an imaging agent.

### Claim 22 (depends on 21)

The kit of claim 21, further comprising a tin-containing reducing agent.
